Non-Surgical Hip Augmentation With a PDLLA-Hyaluronic Acid

Hip contouring is experiencing growing demand within aesthetic medicine, a trend particularly pronounced in Asian populations where cultural preferences emphasize harmoniously proportioned feminine silhouettes. While surgical augmentation remains an option, its inherent procedural risks and protracted recovery periods underscore the need for effective minimally invasive alternatives. Volumetric enhancement using biostimulatory agents, such as poly-D,L-lactic acid (PDLLA), constitutes a non-surgical approach.

This study aimed to evaluate the safety, efficacy, and patient satisfaction of bilateral hip augmentation using PDLLA in a cohort of Korean women.

A prospective case series was conducted involving 30 Korean women (age range: 24-48 years). Participants underwent bilateral hip augmentation between January and June 2024 using a PDLLA-HA hybrid biostimulator (Juvelook G[export name: Juvelook GLAM]). The mean total volume administered was 201.5 mL (range: 180-220 mL; approximately 100 mL per side, range: 90-110 mL). Outcomes were assessed using the Global Aesthetic Improvement Scale (GAIS), patient satisfaction scores (0-10 scale), and standardized photography at the 6-month follow-up.

All 30 participants completed the study protocol. No significant adverse events were reported. Mean patient satisfaction at 6 months was 8.7/10 (±0.9 SD). Based on GAIS assessments, 27 participants (90%) demonstrated moderate to significant aesthetic improvement. Minor transient complications included swelling (n = 13, 43.3%) and mild discomfort (n = 8, 26.7%), all resolving spontaneously within 1 week.

PDLLA hip augmentation, using total volumes approximating 200 mL, demonstrates a favorable safety profile and high efficacy in this cohort of Korean women. The results indicate this approach presents a viable minimally invasive alternative to conventional surgical implant procedures.